-
Mashup Score: 17
New state-of-the-art research and development (R&D) facility at Ludwigshafen to expand discovery and development of new medicines across core therapeutic areas Investment reinforces the importance…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3Environmental, Social & Governance - 4 day(s) ago
We are advancing environmental, social and governance (ESG) initiatives that contribute to the sustainable growth of our company so that we can create positive impact for generations to come. Our ESG framework is built around three pillars that were developed based on our six core material drivers: product innovation, human capital management, product quality and safety, business ethics, patient health and engagement, and patient access and affordability.
Source: www.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 9AbbVie Reports First-Quarter 2024 Financial Results - 8 day(s) ago
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3
The Investor Relations website contains information about AbbVie’s business for stockholders, potential investors, and financial analysts.
Source: investors.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 5AbbVie Reports First-Quarter 2024 Financial Results - 8 day(s) ago
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 7
The Investor Relations website contains information about AbbVie’s business for stockholders, potential investors, and financial analysts.
Source: investors.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 11
Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 161…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 8
The Investor Relations website contains information about AbbVie’s business for stockholders, potential investors, and financial analysts.
Source: investors.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 7
See how the AbbVie-Calico Life Sciences collaboration turns the traditional partnership upside down to tackle age-related diseases.
Source: www.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis - 16 day(s) ago
− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
This week, our Chief Operations Officer & Chief Scientific Officer joined local Rhineland-Palatinate leaders at the groundbreaking for LUnA, our new R&D building in Ludwigshafen, Germany, where we’ve invested 150 million euros in #innovation & #research. https://t.co/wrAQWscydB https://t.co/l3QkTIQEv8